IMPACCT Real-World Evidence Summit on October 27-29, 2026 in Boston, United States

Real-World Evidence has become a critical driver of competitive advantage across pharma and biotech, enabling faster drug development, stronger regulatory submissions, and improved market access outcomes. As FDA and payer expectations evolve, organizations must now deliver decision-grade evidence that is credible, scalable, and aligned across the development lifecycle.

The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into actionable decisions.

Join leading experts from AstraZeneca, Pfizer, Novartis, Boehringer Ingelheim and more to build integrated evidence strategies, accelerate timelines, and maximize the ROI of real-world evidence investment.

URLs:
Tickets: https://go.evvnt.com/3735671-1?pid=10008
Brochure: https://go.evvnt.com/3735671-3?pid=10008

Time: 9:00 AM - 5:00 PM

Venue Details: Courtyard by Marriott Boston Downtown, 275 Tremont Street, Boston, Massachusetts, 02116, United States

Category: Conferences | Science, Health and Medicine

Prices:

Drug Developer Pricing - Full Access Pass: USD 4197.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Service Provider Pricing - Full Access Pass: USD 5197.00,

Service Provider Pricing - Conference Only: USD 3799.00

Speakers: Khaled Sarsour, Vice President and Global Head of Evidence Generation and Advanced Analytics, Astellas Pharma, Zhaoyang Teng, Senior Director and Head of Medical Affairs Statistical Science Quantitative Sciences and Evidence Generation, Astellas Pharma, Jason Zhu, Associate Director – Real-World Data Engineer, AstraZeneca, Sandeep Burugupalli, Head, AI, Clinical Intelligence and Evidence, AstraZeneca, Amit Raval, Director, Real World Evidence Oncology, Bayer, Reg Waldeck, Head, Global Market Access, Bayer, Theresa Cassidy, Executive Director, Real-World Evidence and Epidemiology, Boehringer Ingelheim, Irina Degtiar, Principal Statistician - Therapeutic Area and Methodology, Real World Evidence, Boehringer Ingelheim, Bonnie Donato, Executive Director, Health Economics and Outcomes Research, Cardio-Renal-Metabolic, Boehringer Ingelheim, Ralu Vlad, Senior Vice President and Head, Medical Evidence Generation, Managed Access Programs, and Real-World Evidence, Bristol Myers Squibb, Lucas Oliveira, Director - Real World Evidence and Strategy, Chiesi USA Inc., Gurleen Jhuti, Head, Technical Institute, Policy, Evidence and Access Strategy, Genentech, Vladimir Turzhitsky, Director - Data Science and Outcomes Research, Merck and Co, Colin Kunzweiler, Director - Infectious Disease Epidemiology, Moderna, Chris Blanchette, Vice President - Clinical Data Science, Evidence Short-Term Assignment, Global Medical Affairs, Product and Portfolio Strategy, Novo Nordisk, Lauren Young, Real-World Data Strategy, Emerging Therapies Lead, Novo Nordisk, Scott Kelly, Senior Director, Oncology Real-World Evidence and Epidemiology Lead, Pfizer, Haley Friedler, Global Medical Director - Evidence Generation and Insights and Strategy, Sanofi, Laura Wallace, Head, Global Medical Evidence Generation, Takeda Pharmaceutical, Chitra Karki, Senior Director, Liver/Inflammatory Diseases, Global Evidence and Outcomes, Takeda Pharmaceutical, Xia Wang, Head, RWE Solutions, Global HTA and Payers, Patient Evidence, UCB, Kelly H. Zou, CEO, AI4Purpose, Alexander Cole, Executive Director and Head of Epidemiology and Real-World Science, Alexion Pharmaceuticals, Carmine Colavecchia, Senior Director and Real-World Evidence Scientist, Argenx, Rhys Williams, Vice President - Integrative Evidence Generation, Health Economics and Global Medical Affairs, BeOne Medicines, Eric Xue, Senior Director, Real-world Evidence Statistics, Incyte Corporation, Eugean Jiwanmall, Lead Research Analyst for Medical Policy and Health Technology Evaluation, Independence Blue Cross Family of Companies and Independence Health Group, Patricia Dorling, Senior Director - Health Economics, Outcomes Research and Gene Therapy Portfolio Lead, Insmed, Pamela Bradt, Executive Medical Director and Global Head of RWE and Clinical Epidemiology, Sarepta Therapeutics, Suzanne Morgan, Executive Director and Head of Market Access Stealth, BioTherapeutics, Sandy Leonard, General Manager, LIfe Sciences, ArCADia 10 EN